このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Dimerix バランスシートの健全性

財務の健全性基準チェック /56

Dimerixの総株主資本はA$1.7M 、総負債はA$1.4Mで、負債比率は83.2%となります。総資産と総負債はそれぞれA$15.1MとA$13.4Mです。

主要情報

83.2%

負債資本比率

AU$1.43m

負債

インタレスト・カバレッジ・レシオ	n/a
現金	AU$14.81m
エクイティ	AU$1.72m
負債合計	AU$13.37m
総資産	AU$15.09m

財務の健全性に関する最新情報

Recent updates

Is Dimerix (ASX:DXB) Using Too Much Debt?

Dec 19

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Jul 05

Can Dimerix (ASX:DXB) Afford To Invest In Growth?

Feb 17

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Sep 16

We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate

Jun 02

Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

Sep 20

Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

May 17

Here's What We Think About Dimerix's (ASX:DXB) CEO Pay

Feb 01

財務状況分析

短期負債: DXBの短期資産 ( A$15.1M ) が短期負債 ( A$3.1M ) を超えています。

長期負債: DXBの短期資産 ( A$15.1M ) が長期負債 ( A$10.3M ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: DXB総負債よりも多くの現金を保有しています。

負債の削減: DXBの負債対資本比率は、過去 5 年間で0%から83.2%に増加しました。

貸借対照表

キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: 利益は出ていないものの、 DXBは現在のプラスのフリーキャッシュフローレベルを維持すれば、3 年以上は十分なキャッシュランウェイを有しています。

キャッシュランウェイの予測: DXBは利益は出ていませんが、フリーキャッシュフローがプラスで年間22.7 % 減少しているにもかかわらず、3 年以上は十分なキャッシュランウェイがあります。

Dimerix バランスシートの健全性

財務の健全性 基準チェック /56

主要情報

財務の健全性に関する最新情報

Is Dimerix (ASX:DXB) Using Too Much Debt?

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Can Dimerix (ASX:DXB) Afford To Invest In Growth?

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate

Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

Recent updates

New major risk - Shareholder dilution

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Dimerix Limited has completed a Follow-on Equity Offering in the amount of AUD 20 million.

Now 34% overvalued after recent price rise

Is Dimerix (ASX:DXB) Using Too Much Debt?

Dimerix Limited Announces Appointment of Mark Diamond as Director

Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer

New major risk - Share price stability

Dimerix Limited, Annual General Meeting, Nov 21, 2023

New minor risk - Financial data availability

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

New minor risk - Shareholder dilution

First half 2023 earnings released: AU$0.03 loss per share (vs AU$0.024 loss in 1H 2022)

Can Dimerix (ASX:DXB) Afford To Invest In Growth?

Dimerix Limited Announces Successful Completion of DSMB Review of Phase 3 FSGS Trial

Dimerix Limited Announces That FDA Confirms Inclusion of Paediatrics in Action3 Study of DMX-200 for FSGS

Dimerix Limited Announces Clarity 2.0 Covid-19 Study Outcome

Less than half of directors are independent

Dimerix Limited, Annual General Meeting, Nov 29, 2022

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Full year 2022 earnings released: AU$0.036 loss per share (vs AU$0.032 loss in FY 2021)

Dimerix Limited Confirms CLARITY 2.0 Led Study of COVID-19 Patients

Dimerix Limited Announces New Patent Family Application for DMX-700

Dimerix Limited Announces DMX-700 Study Shows Significant 80% Reduction in Lung Injury

Dimerix Limited Confirms REMAP-CAP Covid-19 Study Analysis Update

Dimerix Limited Announces New Clinical Trial for DMX-200 in Diabetic Kidney Disease

We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate

Dimerix Limited Announces the Recruitment of the First Patient to Its DMX-200 Phase 3 Trial in Patients with FSGS Kidney Disease

Dimerix Limited Announces Approval of Action3 Phase 3 Clinical Trial of DMX-200 in FSGS

Less than half of directors are independent

Dimerix Limited Announces DSMB Change to REMAP-CAP COVID-19 Study

Dimerix Limited Appoints Dr. Ash Soman as Chief Medical Officer

Dimerix Limited Announces Receipt of the First Regulatory Approval in Europe (For Denmark) for Its Pivotal Phase 3 Clinical Trial, Action3

Dimerix Announces Patients Dosed in DMX-200 COVID-19 Phase 3 Study in India

Dimerix Limited Receives Ethics Approval in Australia for Phase 3 Covid-19 Study

Insider recently bought AU$512k worth of stock

Dimerix Limited Recommends DMX-200 Clinical Study in COVID-19 Patients

Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

Dimerix Receives Innovation Passport and ILAP Designation

Dimerix Limited Confirms Phase 3 FSGS Kidney Disease Study Design with EMA

Dimerix Limited Confirms Active Discussions with the FDA on the Phase 3 Study Design in Focal Segmental Glomerulosclerosis

Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

Dimerix Limited Updates of DMX-200 Study in COVID-19 Patients in India

Dimerix Limited Provides an Update on the Clarity 2.0 Study in Patients with COVID-19

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.02 loss in 1H 2020)

Here's What We Think About Dimerix's (ASX:DXB) CEO Pay

Dimerix Limited Plans for Next Study in Diabetic Kidney Disease

New 90-day high: AU$0.29

New 90-day low: AU$0.20

Dimerix Limited Announces Acute Respiratory Distress Syndrome in COVID-19 Patients Protocol Published

Dimerix Limited Announces Additional Positive in Vitro Data to Support Further Development of Its Drug Candidate DMX-700 to Treat Chronic Obstructive Pulmonary Disease

New 90-day low - AU$0.28

Full year earnings released - AU$0.026 loss per share

New 90-day high - AU$0.64

New 90-day high - AU$0.46

財務状況分析

デット・ツー・エクイティの歴史と分析

貸借対照表

キャッシュ・ランウェイ分析

健全な企業の発掘

財務の健全性基準チェック /56